A review of the pharmacokinetics of abacavir (Q34778565)

4 August 2017

1 reference

title

A review of the pharmacokinetics of abacavir (English)

1 reference

4 August 2017

1 reference

1 reference

Geoffrey J Yuen

1

1 reference

4 August 2017

Steve Weller

series ordinal

2

1 reference

4 August 2017

Gary E Pakes

series ordinal

3

1 reference

4 August 2017

1 January 2008

1 reference

Clinical Pharmacokinetics

4 August 2017

1 reference

4 August 2017

47

1 reference

4 August 2017

351-371

1 reference

4 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200847060-00001

4 August 2017

0 references

cites work

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847060-00001

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847060-00001

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847060-00001

The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200847060-00001

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

21 January 2018

1 reference

12 December 2020

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

1 reference

12 December 2020

Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

1 reference

12 December 2020

Abacavir plus lamivudine: a review of their combined use in the management of HIV infection

1 reference

12 December 2020

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection

1 reference

12 December 2020

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

12 December 2020

Mechanisms of action of mycophenolic acid

1 reference

12 December 2020

Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

Abacavir sulfate, lamivudine, and zidovudine (Trizivir).

1 reference

12 December 2020

Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

1 reference

12 December 2020

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial

1 reference

12 December 2020

Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression

1 reference

12 December 2020

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

1 reference

12 December 2020

Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Current uses and future hopes for clinical pharmacology in the management of HIV infection

1 reference

12 December 2020

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

1 reference

12 December 2020

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

12 December 2020

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

12 December 2020

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

1 reference

12 December 2020

Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis

1 reference

12 December 2020

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

1 reference

12 December 2020

Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients

1 reference

12 December 2020

Abacavir: a review of its clinical potential in patients with HIV infection

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

1 reference

12 December 2020

Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function

1 reference

12 December 2020

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

12 December 2020

Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

1 reference

12 December 2020

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients

1 reference

12 December 2020

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

1 reference

12 December 2020

Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food

1 reference

12 December 2020

Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regi

1 reference

12 December 2020

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

1 reference

12 December 2020

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

12 December 2020

Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

1 reference

12 December 2020

Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: The past, the present, and the future

1 reference

12 December 2020

Pharmacodynamics of abacavir in an in vitro hollow-fiber model system

1 reference

12 December 2020

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results

1 reference

12 December 2020

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy

1 reference

12 December 2020

Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999.

1 reference

12 December 2020

Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population

1 reference

12 December 2020

The role of adherence to antiretroviral therapy in the management of HIV infection

1 reference

12 December 2020

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

1 reference

12 December 2020

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study

1 reference

12 December 2020

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

12 December 2020

Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity

1 reference

12 December 2020

An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy

1 reference

12 December 2020

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir

1 reference

12 December 2020

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

12 December 2020

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

12 December 2020

Quantifying HIV-1 proviral DNA using the polymerase chain reaction on cerebrospinal fluid and blood of seropositive individuals with and without neurologic abnormalities.

1 reference

12 December 2020

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

12 December 2020

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

1 reference

12 December 2020

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

1 reference

12 December 2020

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

1 reference

12 December 2020

Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir

1 reference

12 December 2020

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

1 reference

12 December 2020

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption

1 reference

12 December 2020

Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy

1 reference

12 December 2020

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

12 December 2020

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

12 December 2020

Impact of pregnancy on abacavir pharmacokinetics

1 reference

12 December 2020

Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol

1 reference

12 December 2020

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

1 reference

12 December 2020

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

1 reference

12 December 2020

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients

1 reference

12 December 2020

Lamivudine/zidovudine/abacavir: triple combination tablet

1 reference

12 December 2020

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

1 reference

12 December 2020

1 reference

12 December 2020

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults

1 reference

12 December 2020

Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1

1 reference

12 December 2020

Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

1 reference

12 December 2020

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

1 reference

12 December 2020

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

12 December 2020

10.2165/00003088-200847060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference